BIO-WindhoverMar. 16, 2008-Mar. 18, 2008
New York, NY
Preserving Value: To License or Not to LicenseBen Bonifant, Vice President and head of the Business Development Practice, will participate in the opening keynote panel discussion titled "Preserving Value: To License or Not to License." Other panelists include Pfizer, Atlas Venture, Alnylam Pharmaceuticals, and Deerfield Partners.
Preserving Value: To License or Not to License
With M&A increasingly popular among Big Pharma and the overwhelmingly preferred exit for VCs, whether or not to license a key product (and how much of the key product’s rights to license) has become one of the most important strategic challenges for biotechs and their investors. Forgo a significant licensing opportunity -- and forgo the most important source of non-dilutive financing. License out the project -- and potentially destroy the value for a deep-pocketed acquirer. This panel of venture and cross-over investors and biotech companies who have made very different choices about licensing strategies will discuss how they have grappled with the myriad problems embedded in the licensing decision.
Head of Strategic Marketing
(973) 967-2300, x2313